Pfizer's vaccine, called Abrysvo, is already approved and available in the U.S. for adults ages 60 and up. The panel's recommendation puts Pfizer's maternal shot on track to reach the public as RSV begins to spread at higher levels. But younger children and older adults are particularly vulnerable to more severe RSV infections. Each year, the virus kills a few hundred children younger than 5, and 6,000 to 10,000 seniors, according to the CDC. RSV also causes around 58,000 to 80,000 hospitalizations among children younger than 5 years old each year, the CDC said.

---

Persons: Pfizer, Mandy Cohen, Luis Jodar, Pfizer's Abrysvo, Jefferson Jones, Jones Organizations: Disease Control, U.S, Public, CDC, Pfizer, Northern, Drug Administration, FDA, AstraZeneca Locations: U.S, Sanofi